Article
Rheumatology
Eric F. Morand, Gabriel Abreu, Richard A. Furie, Vera Golder, Raj Tummala
Summary: A post hoc analysis reveals that treatment with anifrolumab in patients with SLE leads to earlier, more frequent, and more sustained attainment of LLDAS. LLDAS is highly associated with responses measured by BICLA and SRI(4).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Immunology
Wenqian Wang, Chenran Yue, Sheng Gao, Shuting Li, Jianan Zhou, Jiaqing Chen, Jiahong Fu, Weijian Sun, Chunyan Hua
Summary: Exosomal miRNAs show potential as biomarkers in SLE/LN patients for renal injury diagnosis. Exosomes are considered optimal delivery vehicles due to their high stability, minimal toxicity, low immunogenicity, and specific target effects.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Jun Kikuchi, Hironari Hanaoka, Shuntaro Saito, Tatsuhiro Oshige, Kazuoto Hiramoto, Yuko Kaneko, Tsutomu Takeuchi
Summary: This study aimed to demonstrate the significance of the time to achieve lupus low disease activity state (LLDAS) after remission induction therapy in patients with severely active SLE. The results showed that achieving LLDAS within 12 months may be favorable in patients with severely active SLE.
Article
Rheumatology
Yoshiya Tanaka
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes damage to multiple organs. Current treatments mainly involve glucocorticoids and immunosuppressants, but the development of molecular target drugs with minimal side effects is desired. Research is focused on finding new approaches such as targeted therapies and drugs that modulate the innate and adaptive immune systems.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Lu Xiao, Wei Xiao, Shudian Lin
Summary: This study aimed to identify the key genes related to active renal involvement in patients with systemic lupus erythematosus (SLE). A total of 182 differentially expressed genes (DEGs) were identified, and 12 hub genes were found to be positively associated with SLE Disease Activity Index (SLEDAI). The combination model of these hub genes showed certain diagnostic accuracy in detecting renal involvement with high disease activity in SLE patients.
FRONTIERS IN MEDICINE
(2022)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Rui Tian, Lin Yuan, Yuan Huang, Rui Zhang, Hao Lyu, Shuai Xiao, Dong Guo, Declan William Ali, Marek Michalak, Xing-Zhen Chen, Cefan Zhou, Jingfeng Tang
Summary: Systemic lupus erythematosus (SLE) is a common autoimmune disease characterized by autoantibody production and immune complex deposition. Autophagy plays a crucial role in maintaining cellular homeostasis, and dysfunction in autophagy leads to the accumulation of apoptosis and induction of autoantibodies, contributing to the development of SLE. Traditional Chinese medicines (TCMs), known for their low toxicity and minimal side effects, have been found to modulate autophagy and show potential in the treatment of SLE.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
You Wang, Weikang Shu, Sihan Lin, Jiayue Wu, Meng Jiang, Shumin Li, Chao Liu, Rongxin Li, Congcong Pei, Yajie Ding, Jingjing Wan, Wen Di
Summary: A machine learning-based diagnostic protocol using serum metabolic fingerprints has been developed to accurately assess the activity of systemic lupus erythematosus (SLE) in pregnant women. This method directly extracts metabolic fingerprints from serum samples and analyzes them using an optimized algorithm. The results show that the method can accurately differentiate between active and inactive SLE, providing a new option for precise clinical diagnosis.
Review
Immunology
Feng Chen, Ying Zheng, Xinying Chen, Zhanfa Wen, Youjia Xu, Jinghua Yang, Kaisi Xu
Summary: Belimumab is an important medication for the treatment of cSLE. However, there is a lack of sufficient research on its efficacy and safety, and further studies are needed to validate its clinical value.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Diane L. Kamen, Julie A. Birt, Monica A. Hadi, Elizabeth Gibbons, Donald M. Bushnell, Ren Yu, Laure A. Delbecque, Kirstin Griffing, Anca Askanase
Summary: Many people with SLE experience joint symptoms such as pain, swelling, and stiffness, which can impact physical functioning and work disability. A survey was conducted on adults with SLE to examine the burden and impact of joint symptoms.
Review
Medicine, General & Internal
Fulvia Ceccarelli, Marcello Govoni, Matteo Piga, Giulia Cassone, Francesco Paolo Cantatore, Giulio Olivieri, Alberto Cauli, Ennio Giulio Favalli, Fabiola Atzeni, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula, Fabrizio Conti
Summary: Musculoskeletal involvement is a common manifestation of SLE that affects patients' quality of life and prognosis. Understanding the pathogenetic mechanisms is crucial for developing effective therapeutic approaches.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Kaichi Kaneko, Hao Chen, Matthew Kaufman, Isaak Sverdlov, Emily M. Stein, Kyung-Hyun Park-Min
Summary: Osteonecrosis is a complex and devastating complication of systemic lupus erythematosus, with variable prevalence in SLE patients. The use of high-dose glucocorticoid therapy is strongly associated with the development of osteonecrosis in SLE patients, although the exact pathophysiology and risk factors for osteonecrosis in this population are not fully understood.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Rheumatology
Xiaochan Chen, Xiaowei Shi, Han Xue, Honghua Lv, Lishi Yu, Xiudi Wu, Qiaohong Wang, Huaxiang Wu, Fei Han, Jing Xue
Summary: This multicentre prospective cohort study demonstrates that long-term RTX maintenance therapy has high efficacy and acceptable safety in relapsing or refractory SLE patients who had a clinical response to RTX induction therapy.
Review
Chemistry, Medicinal
Salvatore Di Bartolomeo, Alessia Alunno, Francesco Carubbi
Summary: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with a wide range of clinical manifestations. The respiratory system can be involved in up to 50-70% of patients, with varying severity and treatment approaches depending on specific patterns.
Review
Biochemistry & Molecular Biology
Valeria Rella, Cinzia Rotondo, Alberto Altomare, Francesco Paolo Cantatore, Addolorata Corrado
Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical manifestations. Dysregulation of the immune system due to genetic, hormonal, and environmental factors can lead to various complications, including bone involvement such as osteoporosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)